Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by pSivida Corp. on December 3, 2015. The filing details the results of shareholder votes on director elections, executive compensation, and auditor ratification.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Shareholders approved all proposals presented at the meeting. Key outcomes include:
- Election of Directors: All six nominees (David J. Mazzo, Paul Ashton, Michael Rogers, Peter G. Savas, Douglas Godshall, and James Barry) were elected. Non-votes totaled approximately 9.9 million shares for each nominee.
- CEO Stock Option Grant: Approved with 9,620,898 votes "For" versus 1,296,356 "Against".
- Non-Executive Director Stock Option Grants: Approved for all five directors. Vote counts varied, with "For" votes ranging from approximately 6.9 million to 7.3 million.
- Executive Compensation (Say-on-Pay): Approved on an advisory basis with 8,139,098 votes "For" versus 2,809,807 "Against".
- Auditor Ratification: Deloitte & Touche LLP was ratified for fiscal year 2016 with overwhelming support (20,335,389 "For" vs. 587,179 "Against").
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on future operations, or specific risk factors. It references a definitive proxy statement filed on October 23, 2015, for detailed proposal descriptions.
Investor Verification Checklist
- Verify the total number of shares outstanding and the percentage of votes represented by the "Non Votes" (approx. 9.9 million) to assess shareholder engagement levels.
- Review the October 23, 2015, definitive proxy statement for details on the specific terms of the approved stock option grants.
- Confirm the exact number of shares voted "Against" the CEO compensation and Say-on-Pay proposals to gauge dissent levels.